DLL3 / Tarlatamab：EGFR 突变神经内分泌转化后的探索方向

类型: 转化研究 / 病例报告 发表日期: 2025-09-30 入库日期: 2026-05-21 来源: PubMed / JTO Clinical and Research Reports 标签: EGFR L858R, 小细胞转化, DLL3, Tarlatamab, 临床试验, 探索治疗

Citation

DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed EGFR-Mutant Lung Cancer and Two Cases of Tarlatamab Therapy. JTO Clinical and Research Reports. 2025. PMID: 41256964. DOI: 10.1016/j.jtocrr.2025.100913

Why it matters for mom

This is not standard treatment for lung adenocarcinoma. It matters only if neuroendocrine/small-cell transformation is pathologically confirmed. DLL3-targeted therapy is an emerging SCLC field, and this paper asks whether transformed EGFR-mutant disease can share that target.

Practical takeaways

• If transformation is confirmed, ask whether DLL3 testing is available or useful.
• Tarlatamab is exploratory in transformed EGFR-mutant disease; it is more relevant as a trial/consultation keyword than an immediate plan.
• This should not distract from standard confirmation and standard transformed-SCLC treatment discussions.

Watch terms

• DLL3 IHC
• Tarlatamab
• Neuroendocrine-transformed EGFR-mutant lung cancer
• Transformed SCLC clinical trials